This is a fixed-dose combination of three antiretroviral medicines — dolutegravir, emtricitabine, and tenofovir alafenamide — used together as a complete, once-daily regimen to treat HIV-1 infection. It combines a highly effective integrase inhibitor with two nucleos(t)ide reverse transcriptase inhibitors, using the newer tenofovir alafenamide prodrug associated with less impact on kidney function and bone density than older tenofovir formulations. It is a prescription-only medicine.

• Therapeutic Class: Antiretroviral combination therapy for HIV-1.

• Pharmacological Class: Integrase strand transfer inhibitor (dolutegravir) plus two nucleos(t)ide reverse transcriptase inhibitors (emtricitabine, tenofovir alafenamide).

• Drug Family: Combination antiretroviral therapy (cART).

• ATC Classification: J05AR (Antivirals for treatment of HIV infections, combinations) — specific code varies by regulatory region.

Approved: HIV-1 infection in adults, as a complete once-daily regimen, in regions/programs where this specific combination has been authorised.

Commonly used for: People with HIV needing a simplified, well-tolerated, once-daily regimen combining a high-resistance-barrier integrase inhibitor with a kidney/bone-friendlier tenofovir formulation.

Off-label use (only under medical guidance): Not typically used off-label; use follows HIV treatment guidelines for this combination class.

● Oral tablets (fixed-dose combination): dolutegravir 50 mg / emtricitabine 200 mg / tenofovir alafenamide 25 mg.

Dolutegravir blocks an HIV enzyme called integrase, which the virus needs to insert its genetic material into human cells — a mechanism with a high barrier to resistance. Emtricitabine and tenofovir alafenamide block a different HIV enzyme, reverse transcriptase, by acting as faulty building blocks that stop the virus's genetic material from being copied. Tenofovir alafenamide is a more targeted prodrug that delivers the active drug efficiently into cells at a lower circulating dose, generally resulting in less impact on kidney function and bone density than older tenofovir disoproxil fumarate-based regimens.

• Standard dose: One tablet taken orally once daily, with or without food.

• Condition-wise dose: As with other fixed-dose HIV combinations, individual component dose adjustment isn't possible, so use in patients with significant kidney impairment requires specific guidance from the treating HIV specialist.

• Route: Oral, once daily.

• Missed dose: Take the missed dose as soon as remembered; if close to the next dose, skip it and continue as scheduled — don't double up.

• Overdose: May cause increased side effects related to the individual components; requires medical attention.

• Common: Headache, nausea, diarrhoea, fatigue, and insomnia.

• Serious: Immune reconstitution inflammatory syndrome (a temporary worsening of symptoms as the immune system recovers), liver toxicity, and hypersensitivity reactions linked to dolutegravir; weight gain has also been associated with dolutegravir-based regimens.

• Emergency symptoms: Yellowing of the skin/eyes, signs of an allergic/hypersensitivity reaction (fever, rash, severe fatigue, along with respiratory or gastrointestinal symptoms), or severe abdominal pain.

• Recovery advice: Most common side effects like headache or nausea are mild and often improve within the first few weeks; any new rash accompanied by fever or fatigue should be reported promptly, as it could indicate a hypersensitivity reaction to dolutegravir.

• Pregnancy: Current guidance supports dolutegravir-based regimens in pregnancy in most circumstances; specific guidance should be reviewed with the treating doctor.

• Breastfeeding: Discussed with the treating doctor, in line with broader HIV-in-pregnancy/breastfeeding guidance to prevent transmission.

• Liver disease: Used with caution; liver function is monitored, particularly given the hepatitis B interaction risk.

• Kidney disease: Generally usable with less dose-adjustment concern than older tenofovir disoproxil fumarate-containing regimens, though renal function is still monitored.

• Elderly: Limited specific data; used with routine monitoring.

• Children: Approval and use in children depends on the specific regional product licensing; younger children typically require separate weight-based dosing of the individual components.

● Polyvalent cation-containing products (antacids, calcium, iron supplements): can significantly reduce dolutegravir absorption; these should be separated by several hours or, where appropriate, taken with food.

● Other integrase inhibitors, emtricitabine-, or tenofovir-containing products: should not be combined with this medicine to avoid duplicate dosing.

● Certain anti-seizure and anti-tuberculosis medicines (e.g., carbamazepine, rifampin): can reduce dolutegravir levels, sometimes requiring dose adjustment.

● Metformin: dolutegravir can increase metformin levels, potentially requiring dose adjustment of metformin in patients with diabetes.

● Hepatitis B virus testing before starting and monitoring if the medicine is stopped.

● Kidney function tests periodically.

● HIV viral load and CD4 count to monitor treatment response.

● Weight monitoring, given the association between dolutegravir-based regimens and weight gain in some studies.

Bictegravir/emtricitabine/tenofovir alafenamide, Dolutegravir/lamivudine/tenofovir disoproxil fumarate (TLD), Dolutegravir/lamivudine (a two-drug regimen).

This is itself a fixed triple combination intended as a complete regimen; not combined with other products containing the same three drugs.

● HIV / Antiretroviral Medicines

● Fixed-Dose Combination ART

● Integrase Strand Transfer Inhibitors

1. What Is The Stigma Around HIV And AIDS

2. Top 4 Complementary Therapies For HIV

3.HIV Medications, An Effective Treatment To Live A Healthy Life

1. https://investor.mylan.com/news-releases/news-release-details/mylan-receives-tentative-approval-combination-hiv-treatment

2. https://www.contagionlive.com/view/once-daily-fixed-dose-hiv-combo-drug-from-mylan-receives-tentative-approval-from-fda

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.